Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation

Transplant Infectious Disease

Volumn 9, Issue 1, 2007, Pages 11-15

  Narimatsu, H ^a,b   Kami, M ^c   Kato, D ^a   Matsumura, T ^a   Murashige, N ^d   Kusumi, E ^a   Yuji, K ^a   Hori, A ^d   Shibata, T ^d   Masuoka, K ^a   Wake, A ^a   Miyakoshi, S ^a   Morinaga, S ^a   Taniguchi, S ^a  

^a TORANOMON HOSPITAL   (Japan)

^b TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Cytomegalovirus antigenemia; Enterocolitis; Graft versus host disease

Indexed keywords

AMPHOTERICIN B; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIGEN PP65; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; PREDNISOLONE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ENTEROCOLITIS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MOUTH ULCER; MYCOSIS; NAUSEA; NONHUMAN; PENIS DISEASE; PRIORITY JOURNAL; RASH; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SEIZURE; THROMBOPHLEBITIS; TRANSPLANTATION; UMBILICAL CORD BLOOD; UMBILICAL CORD BLOOD TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENTEROCOLITIS; EXANTHEMA; FEMALE; FOSCARNET; GANCICLOVIR; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WATER-ELECTROLYTE IMBALANCE;

EID: 33846957148     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2006.00161.x     Document Type: Article

References (30)

1. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265-2275.
2. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004; 104: 3813-3820.
3. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276-2285.
4. Barker JN, Weisdorf DJ, DeFor TE, et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003; 102: 1915-1919.
5. Miyakoshi S, Yuji K, Kami M, et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res 2004; 10: 3586-3592.
6. Tomonari A, Iseki T, Ooi J, et al. Cytomegalovirus infection following unrelated cord blood transplantation for adult patients: a single institute experience in Japan. Br J Haematol 2003; 121: 304-311.
7. Saavedra S, Sanz GF, Jarque I, et al. Early infections in adult patients undergoing unrelated donor cord blood transplantation. Bone Marrow Transplant 2002; 30: 937-943.
8. Nguyen Q, Champlin R, Giralt S, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999; 28: 618-623.
9. Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transpl Infect Dis 1999; 1: 165-178.
10. Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071.
11. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601-1607.
12. Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991; 324: 1005-1011.
13. Tomonari A, Iseki T, Takahashi S, et al. Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and bone marrow transplantation. Ann Hematol 2004; 83: 573-577.
14. Wahren B, Oberg B. Reversible inhibition of cytomegalovirus replication by phosphonoformate. Intervirology 1980; 14: 7-15.
15. Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992; 166: 473-479.
16. Ljungman P, Oberg G, Aschan J, et al. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 18: 565-568.
17. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159-1164.
18. Moretti S, Zikos P, Van Lint MT, et al. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant 1998; 22: 175-180.
19. Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994; 48: 199-226.
20. Kodera Y, Morishima Y, Kato S, et al. Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia. Bone Marrow Transplant 1999; 24: 995-1003.
21. Nishihira H, Kato K, Isoyama K, et al. The Japanese cord blood bank network experience with cord blood transplantation from unrelated donors for haematological malignancies: an evaluation of graft-versus-host disease prophylaxis. Br J Haematol 2003; 120: 516-522.
22. Kanda Y, Mineishi S, Saito T, et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 2001; 27: 437-444.
23. Gondo H, Minematsu T, Harada M, et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol 1994; 86: 130-137.
24. Aweeka FT, Jacobson MA, Martin-Munley S, et al. Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 350-357.
25. Nyberg G, Blohme I, Persson H, Svalander C. Foscarnet-induced tubulointerstitial nephritis in renal transplant patients. Transplant Proc 1990; 22: 241.
26. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
27. Deray G, Martinez F, Katlama C, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 1989; 9: 316-321.
28. Bregante S, Bertilson S, Tedone E, et al. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study. Bone Marrow Transplant 2000; 26: 23-29.
29. Chrisp P, Clissold SP. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991; 41: 104-129.
30. Baldanti F, Gerna G. Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and clinical impact. J Antimicrob Chemother 2003; 52: 324-330.